FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307179410> ?p ?o ?g. }

• W4307179410 endingPage "1402" @default.
• W4307179410 startingPage "1387" @default.
• W4307179410 abstract "Abstract Background Patients with refractory or relapsed acute myeloid leukemia (AML) have poor survival, necessitating the exploration of optimized therapeutic strategy. Here, we aimed to investigate clinical outcomes and health‐related quality of life (HR‐QoL) after total therapy, which included allogeneic hematopoietic stem cell transplantation (allo‐HSCT), and prophylactic donor lymphocyte infusion (DLI) in the early phase after transplantation, followed by multiple measurable residual disease (MRD) and graft‐versus‐host disease (GvHD)‐guided DLIs. Methods Consecutive patients who had refractory or relapsed AML and had received non‐T‐cell‐depleted allo‐HSCT at Peking University Institute of Hematology were included in the study. If the patients achieved complete remission at 30 days after transplantation and had no evidence of relapse, severe infection, organ failure, and active GvHD at the time of planned DLI, prophylactic DLI was administered at 30 days after transplantation for human leukocyte antigen (HLA)‐matched related HSCT or at 45‐60 days after transplantation for haploidentical or unrelated HSCT. Subsequently, multiple DLIs were administered based on MRD results and whether they developed GvHD after transplantation. Results A total of 105 patients were eligible. Eighty‐seven patients received prophylactic DLI (group B), while 18 did not receive prophylactic DLI (group A). Among 105 patients, the cumulative incidence of grade 2‐4 acute GvHD and chronic GvHD was 40.6% (95% confidence interval [CI] = 30.6%‐50.6%) and 73.3% (95% CI = 67.4%‐79.2%), respectively. The cumulative incidence of relapse (CIR), transplant‐related mortality (TRM), and leukemia‐free survival (LFS) at 5 years after transplantation were 31.5% (95% CI = 21.9%‐41.1%), 22.1% (95% CI = 11.3%‐32.9%), and 46.4% (95% CI = 36.8%‐56.0%), respectively. In group B, the CIR, TRM, and LFS at 5 years after transplantation were 27.6% (95% CI = 17.6%‐37.6%), 21.6% (95% CI = 11.2%‐32.0%), and 50.8% (95% CI = 40.0%‐61.6%), respectively. At the end of follow‐up, 48 patients survived, and more than 90% of survivors had satisfactory recoveries of HR‐QoL. Conclusions Our study indicated that total therapy is not only associated with decreased CIR, comparable TRM, and better long‐term LFS, but also with satisfactory HR‐QoL for refractory or relapsed AML, compared with those of standard of care therapy reported previously. Therefore, total therapy may be an optimized therapeutic strategy for refractory or relapsed AML." @default.
• W4307179410 created "2022-10-29" @default.
• W4307179410 creator A5002188808 @default.
• W4307179410 creator A5014867566 @default.
• W4307179410 creator A5046424825 @default.
• W4307179410 creator A5046756784 @default.
• W4307179410 creator A5047641392 @default.
• W4307179410 creator A5051030924 @default.
• W4307179410 creator A5055494772 @default.
• W4307179410 creator A5060211823 @default.
• W4307179410 creator A5061407928 @default.
• W4307179410 creator A5065894155 @default.
• W4307179410 creator A5072208411 @default.
• W4307179410 creator A5078632164 @default.
• W4307179410 creator A5087610827 @default.
• W4307179410 creator A5089572713 @default.
• W4307179410 date "2022-10-23" @default.
• W4307179410 modified "2023-10-06" @default.
• W4307179410 title "Optimized therapeutic strategy for patients with refractory or relapsed acute myeloid leukemia: long‐term clinical outcomes and health‐related quality of life assessment" @default.
• W4307179410 cites W193514409 @default.
• W4307179410 cites W1967916642 @default.
• W4307179410 cites W1985540489 @default.
• W4307179410 cites W2000831487 @default.
• W4307179410 cites W2005604237 @default.
• W4307179410 cites W2043216151 @default.
• W4307179410 cites W2055236259 @default.
• W4307179410 cites W2059758284 @default.
• W4307179410 cites W2061660136 @default.
• W4307179410 cites W2085749279 @default.
• W4307179410 cites W2090420626 @default.
• W4307179410 cites W2097192169 @default.
• W4307179410 cites W2120817878 @default.
• W4307179410 cites W2137465585 @default.
• W4307179410 cites W2139623754 @default.
• W4307179410 cites W2141696179 @default.
• W4307179410 cites W2147773887 @default.
• W4307179410 cites W2161557582 @default.
• W4307179410 cites W2278219357 @default.
• W4307179410 cites W2320331489 @default.
• W4307179410 cites W2379365975 @default.
• W4307179410 cites W2496367306 @default.
• W4307179410 cites W2551988754 @default.
• W4307179410 cites W2581367275 @default.
• W4307179410 cites W2610209779 @default.
• W4307179410 cites W2618073389 @default.
• W4307179410 cites W2641696820 @default.
• W4307179410 cites W2727410306 @default.
• W4307179410 cites W2790296924 @default.
• W4307179410 cites W2898523261 @default.
• W4307179410 cites W2941194618 @default.
• W4307179410 cites W3024389092 @default.
• W4307179410 cites W3083045366 @default.
• W4307179410 cites W3083692749 @default.
• W4307179410 cites W3087236808 @default.
• W4307179410 cites W3087258385 @default.
• W4307179410 cites W3119720988 @default.
• W4307179410 cites W3175898740 @default.
• W4307179410 cites W4307179410 @default.
• W4307179410 doi "https://doi.org/10.1002/cac2.12376" @default.
• W4307179410 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36274263" @default.
• W4307179410 hasPublicationYear "2022" @default.
• W4307179410 type Work @default.
• W4307179410 citedByCount "3" @default.
• W4307179410 countsByYear W43071794102022 @default.
• W4307179410 countsByYear W43071794102023 @default.
• W4307179410 crossrefType "journal-article" @default.
• W4307179410 hasAuthorship W4307179410A5002188808 @default.
• W4307179410 hasAuthorship W4307179410A5014867566 @default.
• W4307179410 hasAuthorship W4307179410A5046424825 @default.
• W4307179410 hasAuthorship W4307179410A5046756784 @default.
• W4307179410 hasAuthorship W4307179410A5047641392 @default.
• W4307179410 hasAuthorship W4307179410A5051030924 @default.
• W4307179410 hasAuthorship W4307179410A5055494772 @default.
• W4307179410 hasAuthorship W4307179410A5060211823 @default.
• W4307179410 hasAuthorship W4307179410A5061407928 @default.
• W4307179410 hasAuthorship W4307179410A5065894155 @default.
• W4307179410 hasAuthorship W4307179410A5072208411 @default.
• W4307179410 hasAuthorship W4307179410A5078632164 @default.
• W4307179410 hasAuthorship W4307179410A5087610827 @default.
• W4307179410 hasAuthorship W4307179410A5089572713 @default.
• W4307179410 hasBestOaLocation W43071794101 @default.
• W4307179410 hasConcept C120665830 @default.
• W4307179410 hasConcept C121332964 @default.
• W4307179410 hasConcept C126322002 @default.
• W4307179410 hasConcept C142424586 @default.
• W4307179410 hasConcept C143998085 @default.
• W4307179410 hasConcept C194409129 @default.
• W4307179410 hasConcept C2777408962 @default.
• W4307179410 hasConcept C2778461978 @default.
• W4307179410 hasConcept C2778729363 @default.
• W4307179410 hasConcept C2779695342 @default.
• W4307179410 hasConcept C2779972918 @default.
• W4307179410 hasConcept C2911091166 @default.
• W4307179410 hasConcept C61511704 @default.
• W4307179410 hasConcept C71924100 @default.
• W4307179410 hasConcept C87355193 @default.
• W4307179410 hasConcept C88879693 @default.
• W4307179410 hasConceptScore W4307179410C120665830 @default.

• next